Navigate to
-
Zolgensma, which was FDA approved in May 2019, is administered as an intravenous (IV) infusion, with dosing based on patient weight, in pediatric patients under 2 years of age with SMA caused by...
-
Generic Name Brand Name Manufacturer Indication(s) Route of Administration Month Approved* aprocitentan Tryvio® Idosia Difficult-to-control or resistant hypertension Oral March budesonide Eohilia™...
-
Editorial team The American College of Physicians (ACP) has released a clinical practice guideline on use of pharmacological treatment for prevention of episodic migraine, defined as one to 14...
-
Pipeline (late-stage development) Name Manufacturer Route of administration Mechanism of action Proposed / studied indication Status Tividenofusp alfa (DNL310) AstraZeneca IV a fusion protein ERT...
-
Critical updates in an ever-changing environment.
Prime Article: Research & Publications PA Research & Publications: Drug Approvals -
Critical updates in an ever-changing environment
Prime Article: Research & Publications PA Research & Publications: Drug Approvals -
Shortage Updates Eli Lilly’s tirzepatide (Zepbound) is reported as currently available in all strengths, as is the T2DM formulation of tirzepatide (Mounjaro). Additionally, all strengths of Novo...
-
Generic Name Brand Name Brand Manufacturer Indication Approval Month* chikungunya vaccine, live Ixchiq® Valneva Austria Prevention of disease caused by Chikungunya virus November meningococcal...